Pfeiffer Vacuum apprentices win award for virtual training film

Avoids translation misunderstandings as pumps firm expands into Asia

Four apprentices at German pump manufacturer Pfeiffer Vacuum have won the Hessenmetall ‘My Future’ contest for young blood.

Alena Bölzer, Meike König, Oxana Pozdeev and Lisa Weichl won the ‘Unique products and services’ category for their virtual training films, which explain the steps involved in handling individual turbo pumps and other Pfeiffer Vacuum products. The films are practically speech-free so that any misunderstandings in language translation are avoided.

‘We are proud of our young employees,’ said Matthias Wierner, executive board member responsible for marketing, production and development at Pfeiffer Vacuum Technology. ‘They have not only had a great idea and implemented it well but have also presented their results professionally. Pfeiffer Vacuum will this year become even more international with a clear orientation towards Asia. We are very pleased that this situation is being addressed constructively and innovatively by all our staff.’

The company recently set up a subsidiary in São Paulo, Brazil and now has its own subsidiaries in Brazil, Russia, India and China.

Pfeiffer Vacuum reported unaudited sales of €220.5m in 2010, an increase of 21%.

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
Subscribe now